



AVIZAT

Director CSUD.....

VERIFICAT ÎNDEPLINIRE STANDARDE I.O.S.U.D. - UMFC

DA NU

Director Școală doctorală.....

FIȘA DE VERIFICARE

a îndeplinirii standardelor I.O.S.U.D. Universitatea de Medicină și Farmacie „Carol Davila” București
în vederea obținerii atestatului de abilitare

Domeniile de doctorat: Medicină, Farmacie

I. Date despre candidat

Nume: POPP

Prenume: ALINA-MIHAELA

Gradul didactic/de cercetare: Conferentiar Universitar

Încadrat în prezent în învățământul superior:

DA NU

Disciplina Pediatrie 1, Departamentul 7, Facultatea de Medicina, Universitatea de Medicina si Farmacie
„Carol Davila” Bucuresti

Medic/Farmacist rezident/specialist/primar:

DA NU

Ordinul de confirmare: OMS 1200/2009

II. Date privind îndeplinirea condițiilor de abilitare

Doctor în științe

DA NU

Titlul tezei de doctorat: Boala Celiaca la copil si adolescent; corelatii anatomo-clinice



Ordinul de confirmare: OMS 5764/2006

III. Date numerice privind îndeplinirea standardelor minime naționale, conform anexelor nr. 20 și 23 ale Ordinului Ministrului Educației Naționale și Cercetării Științifice nr. 6129/20.12.2016

1. Articole publicate în reviste cotate ISI în calitate de autor principal

Criteriul	Standard minim	Realizat
Număr articole publicate în reviste cotate ISI în calitate de autor principal	10	14

Criteriu îndeplinit: DA NU

Lista articolelor ISI publicate în calitate de autor principal: autori, titlu articol, revistă, an, volum, pagini, factor de impact

AP1. Enache I, Jinga M, Palaga A, Balaban V, Galos F, D-M Macovei, Popp A. *Impact of ESPGHAN non-biopsy strategy of celiac disease treatment in children*. Front. Pediatr. 2025.13:1546711. FI 2.1

AP2. Popp A, Laurikka P, Czika D, Kurppa K. *The role of gluten challenge in the diagnostic of celiac disease: a review*. Exp. Rev. Gastroenterol Hepatol. 2023 Jul-Dec;17(7):691-700. FI 3.8

AP3. Popp A, Taavela J, Graziano P, Parente P, Covelli C, Lamacchia C, Andriulli A, Maki M, Isola J. *A new intraepithelial gammadelta T-Lymphocyte marker for celiac disease classification in formalin-fixed paraffin-embedded (FFPE) Duodenal Biopsies*. Dig Dis Sci. 2021 Oct 66 (10):3352-3358. FI 3.487

AP4. Popp A, Arvola T, Taavela J, Kivela L, Ene A, Laurila K, Saavalainen P, Maki M, Kurppa K. *Nonbiopsy approach for celiac disease is accurate when using exact duodenal histomorphometry: prospective study in two countries*. J Clin Gastroenterol. 2021 Mar 1;55(3):227-232. FI 3.174

AP5. Popp A, Mäki M. *Changing pattern of childhood celiac disease epidemiology; contributing factors*. Front Pediatr. 2019 Aug 29;7:357. FI 2.634

AP6. Popp A, Kivela L, Fuchs V, Kurppa K. *Diagnosing celiac disease: towards wide-scale screening and serology-based criteria?* Gastroenterol Res Pract. 2019 Aug 6;2019:2916024. FI 1.806

AP7. Popp A, Mäki M. *Gluten-Induced Extra-Intestinal Manifestations in Potential Celiac Disease-Celiac Trait*. Nutrients 2019 Feb 1;11(2):320. FI 4.546

AP8. DV Balaban, A Popp, A Beata, F Vasilescu, M Jinga. *Diagnostic accuracy of red blood cell distribution width-to-lymphocyte ratio for celiac disease*. Revista Romana de Medicina de Laborator 2018 26 (1): 45-50. FI 0.8 (autor corespondent)

AP9. Taavela J, Popp A, Korponay-Szabo IR, Ene A, Vornanen M, Saavalainen P, Lahdeaho ML, Ruuska T, Laurila K, Parvan A, Anca I, Kurppa K, Mäki M. *A prospective study on the usefulness of duodenal bulb biopsies in celiac disease diagnosis in children: urging caution*. Am J Gastroenterol. 2016 Jan 111(1):124-133. FI 9.566 (2 primi autori)



AP10. Popp A, Jinga M, Jurcut C, Balaban V, Bardas C, Laurila K, Vasilescu F, Ene A, Anca I, Maki M. *Fingertip rapid point-of-care test in adult case-finding in coeliac disease.* BMC Gastroenterol. 2013 Jul 12;13(1):115. FI 2.113

AP11. Popp A, Mihiu M, Munteanu M, Ene A, Dutescu M, Colcer F, Raducanu D, Laurila K, Anca I, Maki M. *Prospective antibody case finding of celiac disease in Type-1 diabetes children. Need of biopsy revisited.* Acta Paediatr. 2013 Mar 102(3): e102-106. FI 1.842

AP12. Alina Popp, Ciprian Jurcuț, Daniel Vasile Balaban, Mihai Șotcan, Kaija Laurila, Mariana Jinga. *Severe Alveolar Hemorrhage – What's in it for the Gastroenterologist?* J Gastrointest Liver Dis, December 2016, 25 (4): 555-558. FI 1.837

AP13. Jinga M, Jurcut C., Vasilescu F., Balaban V.D., Maki M., Popp A. *Celiac Gluten Sensitivity in an Adult Wman with Autoimmune Thyroiditis* Acta Endo (Buc) 2014, 10 (1): 128-133. FI 0.268

AP14. Mariana Jinga, Daniel Vasile Balaban, Ileana Peride, Andrei Niculae, Irina Monica Duțescu, Florina Vasilescu, Markku Mäki, Alina Mihaela Popp. *Crypt hyperplastic enteropathy in distal duodenum in Helicobacter pylori infection - report of two cases without evidence of celiac disease* Rom J Morphol Embryol. 2017;58(2):685-688. FI 0.912

2. Articole publicate în reviste cotate ISI în calitate de coautor

Criteriul	Standard minim	Realizat
Număr articole publicate în reviste cotate ISI în calitate de coautor	5	31

Criteriu îndeplinit: DA NU

Lista articolelor ISI publicate în calitate de coautor: autori, titlu articol, revistă, an, volum, pagini, factor de impact

CA1. Dotsenko V, Tewes B, Hils M, Pasternack R, Isoa J, Taavela J, Popp A, Sarin J, Huhtala H, Hiltunen P, Zimmerman T, Mohrbacher R, Greinwald R, Lundin K, Schuppan D. *Transcriptomic analysis of intestine following administration of a transglutaminase 2 inhibitor to prevent gluten-induced intestinal damage in celiac disease.* Nat Immunol 2024 Jul;25(7):1218-1230. FI 27.8

CA2. Paun AG, Popescu A, Ungureanu AI, Trusca R, Popp A, Dumitriu C, Buica GO. *Anti-tissue transglutaminase IgA antibodies presence determination using electrochemical square wave voltammetry and modified electrodes based on polypyrrole and quantum dots.* Biosensors 2025 Jan;15(42):1-17. FI 4.9

CA3. Dumitriu C, Pandeale Am, Mindroiu MV, Iazar OA, Popp A, Enachescu M, Buica GO. *Electrochemical detection of antitransglutaminase antibody using quantum dots-doped polypyrrole-modified electrode.* Microchimica Acta 2024 191-543. FI 5.3

CA4. Balaban DV, Coman LI, Enache IC, Mardan CM, Dima A, Jurcuț C, Balaban M, Costache RS, Ioniță-Radu F, Popp A, et al. *Prevalence of Coagulopathy in Patients with Celiac Disease: A Single-Center Retrospective Case-Control Study.* Gastroenterology Insights. 2023; 14(4):463-474. FI 2.9



CA5. Lupu A, Jechel E, Mihai CM, Mitrofan E, Fotu S, Starcea I, Iniouc I, Mocanu A, Ghica D, Popp A, Munteanu D, Sasaran MO, Salaru DL, Lupu VV. *The footprint of microbiome in pediatric asthma – a complex puzzle for balanced development*. *Nutrients*. 2023 Jul 24;15(14):3278. FI 4.8

CA6. Lupu VV, Ghiciuc CM, Stefanescu G, Mihai CM, Popp A, Ssaran Mo, Bozomitu L, Starcea IM et al. (including Popp A). *Emerging role of the gut microbiome in post-infectious irritable bowel syndrome: A literature review*. *World J of Gastroenterol*. 2023 Jun 7;29(21):3241-3256. FI 4.3

CA7. Balaban DV, Enache I, Ciocina M, Popp A, Jinga M. *Pancreatic involvment in celiac disease*. *World J Gastroenterol*. 2022 Jun 28;28(24):2680-2688. FI 4.3

CA8. Tye-Din J, daveson AJM, Goel G, Goldstein K, Hond H, Noff R, Popp A, Taavela J, Maki M, Isola J, Williams L, Truitt K, Anderson RP, RESET CeD Study Group. *Efficacy and safety of gluten peptide-based antigen-specific immunotherapy (Nexvax2) in adults with coeliac disease after bolus exposure to gluten (RESET CD): an interim analysis of a terminated randomised double-blind, placebo-controlled a phase2 study*. *Lancet Gastroenterol Hepatol*. 2023 May;8(5):446-479. FI 30.9

CA9. Feketea G, Popp A, Ionescu DM, Berghea EC. *Case report: Food Protein Induced Protein Losing enteropathy (FPIPLE) in infancy*. *Fron Nutr* 2022 Jan31;9:810409. FI 5.0

CA10. Mearin LM, AgardhD, Antunes H, Al-toma A, Aurricchio R, Castillejo G, Catassi C, Ciacci C, Discepolo V, Dolinsek J, Donat E, Gillet P, Guandalini S, Husby S, Koletzko S, Koltei T, Korpononay-Szabo IR, Kurppa K, Lionetti E, Marild K, Ojinaga EM, Meijer C, Monarche C, Polanco I, Popp A, Roca M, Rodrigues-Herrera A, Shamir R, Stordal K, Troncone R, Valitutti F, Vrendeule A, Wessels M, Whiting P, on behalf of the ESPGHAN CD SIG. *ESPGHAN position paper on managemenet and fllow-up of chidlren and adolescents with celiac disease*. *J Pediatr Gastroenterol.Nutr* 2022 (75), 3:369-386 FI 2.9

CA11. Wessels M, Auricchio R, Dolinsek J, Donat E, Gillett P, Mårild K, Meijer C, Popp A, Mearin ML. *Review on pediatric coeliac disease from a clinical perspective*. *European Journal of Pediatrics* 2022;181:1785-1795. FI 3.6

CA12. Enache I, Balaban DV, Vasilescu F, Jurcut C, Ionita-Radu F, Popp A, Matei D and Jinga M. *Upper Gastrointestinal Tract Associated Lesions in Patients with Newly Diagnosed Celiac Disease*. *Gastroenterol. Insights* 2022, 13, 77–86. FI 1.5

CA13. Ciacci C, Bai JC, Holmes G, et al. (including Popp A). *Serum anti-tissue transglutaminase IgA and prediction of duodenal villous atrophy in adults with suspected coeliac disease without IgA deficiency (Bi.A.CeD): a multicentre, prospective cohort study*. *Lancet Gastroenterology Hepatol*. 2023 Nov;8(11):1005-1014. FI 30.9

CA14. Andriulli A, Bevilacqua A, Palmieri O, Latiano A, Fontana R, Gioffreda D, Castellana S, Mazza T, Panza A, Grandone E, di Mauro L, Decina I, Tricarico M, Musaico D, Maki M, Isola J, Popp A, Taavela J, Petrussi L, Sionigaglia M, Crebo MR, Lammachi C. *Healthy and pro-inflammatory gut ecology plays a crucial role in the digestive and tolerance of a novel Gluten Friendly™ bread in celiac suspects: a randomized, double blind, placebo control „in vivo” study*. *Food & Function*. 2022, Feb7;13(3):1299-1315. FI 4.94

CA15. Schuppan D, Maki M, Lundin KEA, Isola J, Firesnig-sosnik T, Taavela J, Popp A, Kokenpato J, Langhorst J, Hovde O, Lahdeaho M_L, Fusco S, Schumman M, Zeits J, Morhbacher R, Greinwald R. *A randomized trial of a transglutaminase 2 Inhibitor in celiac disease*. *N Engl J Med*. 2021 Jul 1;385(1):35-45. FI 176



CA16. Dotsenko V, Oittinen M, Taavela J, Popp A, Peraaho M, Staff S, Sarin J, Leon F, Isola J, Maki M, Viiri K. *Genome-wide transcriptomic analysis of intestinal mucosa in celiac disease patients on a gluten-free diet and postgluten challenge*. Cell Mol Gastroenterol Hepatol. 2021;11(1):13-32. FI 8.79

CA17. Virta J, Hannula M, Tamminen I, Lindfors K, Kaukinen K, Popp A, Taavela J, Saavalainen P, Hiltunen P, Hyttinen J, Kurppa K. *X-ray microtomography is a novel method for accurate evaluation of small-bowel mucosal morphology and surface area*. Sci Rep. 2020 Aug 4;10(1):13164. FI 3.998

CA18. Husby S, Koletzko S, Korponay-Szabo IR, Kurppa K, Mearin ML, Ribes-Konickx C, Shamir R, Troncone R, Auricchio R, Castillejo G, Christensen R, Dolinsek J, Gillett P, Hrobjartsson A, Koltai T, Mäki M, Nielsen SM, Popp A, Stordal K, Werkstetter K, Wessels M. *European Society Paediatric Gastroenterology, Hepatology and Nutrition Guidelines for Diagnosing Coeliac Disease 2020*. J Pediatr Gastroenterol. Nutr 2020 Jan 70(1):141-156. FI 2.937

CA19. Gustafsson I, Repo M, Popp A, Kaukinen K, Hiltunen P, Arvola T, Taavela J, Vornanen M, Kivelä L, Kurppa K. *Prevalence and diagnostic outcomes of children with duodenal lesions and negative celiac serology*. Dig Liver Dis. 2020 Mar;52(3):289-295. FI 3.570

CA20. Lähdeaho ML, Scheinin M, Vuotikka P, Taavela J, Popp A, Laukkanen J, Koffert J, Koivuova OP, Pesu M, Kivelä L, Lovró Z, Keisala J, Isola J, Parnes JR, Leon F, Mäki M. *Safety and efficacy of AMG 714 in adults with coeliac disease exposed to gluten challenge: a phase 2a, randomised, double-blind, placebo-controlled study*. Lancet Gastroenterol Hepatol. 2019 Dec;4(12):948-959. FI 13.3

CA21. Taavela J, Viiri K, Popp A, Oittinen M, Dotsenko V, Peräaho M, Staff S, Sarin J, Leon F, Mäki M, Isola J. *Histological, immunohistochemical and Mrna gene expression responses in coeliac disease patients challenged with gluten using PAXgene fixed paraffin-embedded duodenal biopsies*. BMC Gastroenterol. 2019 Nov 15;19(1):189. FI 2.3

CA22. Kivelä L, Popp A, Arvola T, Huhtala H, Kaukinen K, Kurppa K. *Long-term health and treatment outcomes in adult coeliac disease patients diagnosed by screening in childhood*. United European Gastroenterol J. 2018 Aug;6(7):1022-1031. FI 3.2

CA23. Ludvigsson J, Ciacci C, Green P, Kaukinen K, Korponay-Szabo IR, Kurppa K, Murray JA, Lundin KEA, Maki MJ, Popp A, Reilly NR, Rodriguez-Herrera A, Sanders DS, Schuppan D, Sleet S, Taavela J, Vorhees K, Walker MM, Leffler DA. *Outcome measures in coeliac disease trials: the Tampere recommendations*. Gut 2018 Aug;67(8):1410-1424. FI 16.6

CA24. Jinga M, Popp A, Balaban DV, Dima A, Jurcut C. *Physicians' attitude and perception regarding celiac disease: A questionnaire-based study*. Turk J Gastroenterol. 2018 Jul;29(4):419-426. FI 1.1

CA25. Goel G, King T, Daveson AJ, Andrews JM, Krishnarajah J, Krause R, Brown GJE, Fogel R, Barish CF, Epstein R, Kinney TP, Miner PB Jr, Tye-Din JA, Girardin A, Taavela J, Popp A, Sidney J, Mäki M, Goldstein KE, Griffin PH, Wang S, Dzuris JL, Williams LJ, Sette A, Xavier RJ, Sollid LM, Jabri B, Anderson RP. *Epitope-specific immunotherapy targeting CD4-positive T cells in coeliac disease: two randomised, double-blind, placebo-controlled phase 1 studies*. Lancet Gastroenterol Hepatol. 2017 Jul;2(7):479-493. FI 13.3

CA26. Werkstetter KJ, Korponay-Szabó IR, Popp A, Villanacci V, Salemme M, Heilig G, Lillevang ST, Mearin ML, Ribes-Konickx C, Thomas A, Troncone R, Filipiak B, Mäki M, Gyimesi J, Najafi M, Dolinšek J, Dydensborg Sander S, Auricchio R, Papadopoulou A, Vécsei A, Sztanyai P, Donat E, Nenna R, Alliet P, Penagini F, Garnier-Lengliné H, Castillejo G, Kurppa K, Shamir R, Hauer AC, Smets F, Corujeira S, van Winckel M, Buderus S, Chong S, Husby S, Koletzko S; ProCeDE study group. *Accuracy in Diagnosis of Celiac Disease Without Biopsies in Clinical Practice*. Gastroenterology 2017 Oct;153(4):924-935. FI 15.7



CA27. Oittinen M, Popp A, Kurppa K, Lindfors K, Maki M, Kaikkonen MU, Viiri K. *Polycomb repressive complex 2 Enacts Wnt Signaling in Intestinal Homeostasis and Contributes to the Instigation of Stemness in Diseases Entailing Epithelial Hyperplasia or Neoplasia*. Stem Cells 2017 Feb;35(2):445-457. FI 5.9

CA28. Balaban DV, Popp A, Lungu AM, Costache RS, Anca IA, Jinga M. *Ratio of spleen diameter to red blood cell distribution width: a novel indicator for celiac disease*. Medicine (Baltimore) 2015 Apr;95(15):e726. FI 5.7

CA29. Suci N, Pop L, Panaitescu E, Suci ID, Popp A, Anca I. *Fetal and neonatal outcome in celiac disease*. The Journal of Maternal-Fetal and Neonatal Medicine 2014 May;27(8):851-855. FI 1.0

CA30. Taavela J, Koskinen O, Huhtala H, Lahdeaho ML, Popp A, Laurila K, Collin P, Kaukinen K, Kurppa K, Maki M. *Validation of morphometric analyses of small intestinal biopsies readouts in celiac disease*. PLOS One. 2013, Oct 11;8(10):e76163. FI 2.8

CA31. Troncone R, Ivarsson A, Szajewska H, Mearin ML; Members of European Multistakeholder Platform on CD (CDEUSSA) incl. Stanescu A. *Review article: future research on celiac disease-a position report from the European multistakeholder platform on celiac disease (CDEUSSA)*. Aliment Pharmacol Ther. 2008 FI 4.4

3. Factorul cumulat de impact pentru articolele publicate ca autor principal în reviste cotate ISI (FCIAP)

Criteriul	Standard minim	Realizat
(ISI) Factor cumulat de impact autor principal	10	38.885

Criteriu îndeplinit: DA NU

4. Indexul Hirsch

Criteriul	Standard minim	Realizat
Index Hirsch	6	18 (Web of Science)

Criteriu îndeplinit: DA NU

Note asupra metodei de calcul:

1. O revistă cotate ISI este o revistă pentru care Thomson Reuters calculează și publică factorul de impact în „Journal Citation Reports”;
2. Autorul sau autorii principali ai unei publicații se consideră a fi oricare dintre următorii:
 - a. Primul autor
 - b. Autorul corespondent
 - c. Alți autori, a căror contribuție este indicată explicit în cadrul publicației a fi egală cu contribuția primului autor sau a autorului corespondent



UNIVERSITATEA DE MEDICINĂ ȘI FARMACIE „CAROL DAVILA“ DIN BUCUREȘTI



Str. Dionisie Lupu 37, sector 2, București, 020021, România, www.umfed.ro, email: rectorat@umfed.ro

d. Ultimul autor

3. În analiză vor fi incluse articole originale și reviews. În cazul publicațiilor în reviste cu factor de impact mai mare decât 3, pot fi luate în considerare și alte tipuri de publicații în extenso (nu rezumate).
4. Articolele din cadrul standardelor minimale și obligatorii trebuie să fie **publicate și indexate**, nu în curs de publicare (nu se acceptă adevărnițe).
5. Factorul cumulat de impact va fi calculat pentru articolele la care candidatul este autor principal (FCIAP). FCIAP = suma factorilor de impact ai articolelor publicate de autor în calitate de autor principal în reviste cotate ISI; **factorul de impact este cel din anul publicării articolului.**
6. Va fi luat în considerare Indexul Hirsch calculat utilizând ISI Web of Science, Core Collection, Thomson Reuters, pentru întreaga carieră a candidatului („all years”);

Confirm prin prezenta că datele menționate mai sus sunt reale și se referă la propria mea activitate profesională și științifică

Data

2/04/2025

Semnătura candidatului,
